RECCE PHARMACEUTICALS LTD
ABN 73 124 849 065

Appendix 4E

Final Report for the financial year ended 30 June 2024

Current Reporting Period: **30 June 2024**

Previous Reporting Period: **30 June 2023**

Results for Announcement to the Market

	12 months to 30 June 2024 $	12 months to 30 June 2023 $	% Change
Revenue from ordinary activities	-	-	0%
Loss from ordinary activities after tax attributable to members	(17,661,714)	(13,077,422)	35%
Net loss for the period attributable to members	(17,661,714)	(13,077,422)	35%

Brief Explanation of Results

Operational Report

During the reporting period, significant advances were made in support of the development of the Company's synthetic anti-infective programme. Some of the highlights for the year were as follows:

- RECCE® 327 (R327) added to the World Health Organization's list of Antibacterial Products in Clinical Development
- Total of A$11.17m received in R&D Rebate Advance Payments
- Australian Government awarded AUD $54,947,284 Advanced Overseas Finding across Recce Pharmaceuticals Pty Ltd infectious disease portfolio
- US Department of Defence grants funding for Burn Wound Programme of US$2 million (approx. A$3 million). Funding will accelerate the development and evaluation of R327G as a gel-based treatment to rapidly resolve burn wound infections and minimise the onset of bacteremia complications in a military setting
- Established a strategic opportunity in South-East Asia to accelerate clinical anti-infective portfolio including a signed Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana Biotechnologies
- Recce to continue strategic partnership with Murdoch Children's Research Institute following positive results for R327 against Gonorrhoea and Mycobacterium abscessus lung infections and Escherichia coli
- New Family 4 patent granted in Australia, Canada and Israel and Family 2 patent granted in China for RECCE® Anti-Infectives

Appendix 4E

Final Report for the financial year ended 30 June 2024

Brief Explanation of Results (Continued)

Clinical progress

- Phase I intravenous (I.V.) clinical trial of R327 in 80 human subjects - complete and independently verified results released
- Phase I/II UTI/Urosepsis Rapid Infusion trial complete & positive efficacy data reported from 25 subjects dosed across various infusion times
- Human Research Ethics Committee (HREC) approval received to commence a Phase II clinical trial assessing R327 as a topical, broad-spectrum gel applied to Acute bacterial skin and skin structure infections (ABSSSI)
- Reported positive results from patients with diabetic foot infections (DFI) treated with R327 under TGA Special Access Scheme – five (5) patients dosed with complex infections unable to be treated by existing antibiotics – surgery/amputation was averted and wound healing observed for all patients
- Positive Human Efficacy Data from Phase I/II trial evaluating R327 Gel in patients with DFIs and expanded trial to additional domestic and international sites

Financial Report

The operating loss has increased to $17,661,714 (2023: loss of $13,077,422) as a result of increased expenditure in consulting and research and development costs. The annual loss was after a R&D tax incentive of $4,906,010 (2023: $4,311,202).

The loss per share has increased during the year to 9.97 cents (2023: 7.52 cents).

The Group's focus is on progressing RECCE® 327 into human clinical trials.

Dividends

	Amount per Security	Percentage Franked
Final Dividend	Nil	N/A
Interim Dividend	Nil	N/A
Date the Dividend is Payable:	N/A	N/A
Record Date for determining entitlements to the Dividends:	N/A	N/A

The Company did not declare a dividend during the financial year and has not declared a dividend since the end of the financial year.

Net Tangible Assets per Security

As at 30 June 2024 (cents)	(4.67)
As at 30 June 2023 (cents)	(1.45)